Rituximab in the Treatment of Non-Infectious Uveitis: A Review

Haixing Cao,Xiang Ma

DOI: https://doi.org/10.2147/jir.s477708

IF: 4.5

2024-09-29

Journal of Inflammation Research

Abstract:Haixing Cao, Xiang Ma Department of Ophthalmology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning Province, People's Republic of China Correspondence: Xiang Ma, Department of Ophthalmology, the First Affiliated Hospital of Dalian Medical University, 222 Zhongshan Road, Dalian City, Liaoning Province, People's Republic of China, Tel +8618098876399, Email Non-infectious uveitis (NIU) is an immune-mediated disorder manifesting as ocular pain, redness, floaters, and photophobia, and is a leading cause of preventable blindness. Managing NIU presents considerable challenges due to the condition's resistance to high-dose corticosteroids and various immunotherapies. This review assesses the efficacy and safety of rituximab (RTX) in the treatment of NIU, based on individual case reports and small-scale studies. A cohort of 78 patients (20 males, 58 females), with a mean onset age of 32.3 years (range 8– 72), was analyzed. Juvenile idiopathic arthritis (JIA) was the most frequently associated comorbidity, affecting 28 patients, while anterior uveitis was the predominant subtype, observed in 26 of 47 cases. Prior to RTX therapy, patients had been treated with an average of 1.7 conventional immunosuppressive agents (range 0– 5) and 1.1 biologics (range 0– 4). RTX was introduced following the failure of high-dose corticosteroids, immunosuppressive drugs, and biologics to control the uveitis. The median time from diagnosis to RTX initiation was 7.7 years (range 0.25– 21). Post-RTX, 44.2% of patients experienced improvement in visual acuity, 79.5% achieved resolution of ocular inflammation, and 8.9% showed partial improvement. Additionally, 81.1% were able to reduce their corticosteroid dosage. Overall, 88.6% (69 out of 78) demonstrated a positive response to RTX treatment. These findings indicate that RTX may serve as an effective therapeutic option for NIU unresponsive to steroids and multiple immunotherapies. It may also warrant consideration as a potential first-line treatment in certain cases. Keywords: non-infectious uveitis, Uveitis, rituximab, RTX, CD20 targeting Non-infectious uveitis (NIU) is an immune-mediated disorder presenting with symptoms such as ocular pain, redness, floaters, and photophobia, and is recognized as a leading cause of preventable blindness. 1 NIU encompasses various conditions, including juvenile idiopathic arthritis (JIA), Behçet's disease, sarcoidosis, multifocal choroiditis, multiple sclerosis, granulomatous polyangiitis, rheumatoid arthritis, serpiginous choroiditis, sympathetic ophthalmia, Vogt-Koyanagi-Harada syndrome(VKH), and birdshot retinochoroidopathy. 2,3 The complications of uveitis, which can result in vision loss, include early manifestations such as cystoid macular edema and vitreous haze, and late-stage complications like cataracts, glaucoma, 3 and irreversible retinal damage. 4 Prompt and accurate diagnosis, involving the exclusion of masquerade syndromes, is crucial for initiating early and effective intervention. 5,6 Corticosteroids are the cornerstone of initial NIU management, delivered systemically, locally via periocular or intravitreal routes, or through intravitreal implants. However, systemic corticosteroids are associated with significant adverse effects, including cataracts, glaucoma, diabetes, and osteoporosis, making their long-term use unfavorable. 4,7–10 For patients with severe or chronic NIU who exhibit inadequate response to corticosteroids, or for those unable to tolerate them or experiencing disease recurrence upon steroid tapering, second-line therapies involve immunosuppressants such as methotrexate, mycophenolate mofetil, and cyclosporine. 11–13 These agents allow for corticosteroid-sparing regimens, reducing related complications. In cases where disease activity persists or these treatments are not tolerated, particularly in patients with a high risk of vision loss or systemic diseases linked to uveitis, biologics like adalimumab may be employed. 14,15 Adalimumab has demonstrated particular efficacy in managing uveitis associated with pediatric rheumatic diseases, 16 with pooled response rates approximating 68.0% (95% CI: 65.4–70.6%). 17 While anti-TNFα therapies generally induce clinical improvement, they may fail to control intraocular inflammation in some patients, may be contraindicated, or discontinued due to adverse effects, posing substantial clinical challenges. 18 Rituximab (RTX), a chimeric mouse/human monoclonal antibody targeting the CD20 antigen on naive and memory B cells, has emerged as a potent therapy for autoimmune diseases resistant to conventional immunosuppressive regimens, through its ability to deplete pathogenic B cells. 19–23 The efficacy of anti-CD20-mediated B-cell d -Abstract Truncated-

immunology